During the corresponding time, Cytek Biosciences Inc recorded a revenue increase by 5.1 % year on year, sequentially revenue fell by -30.39 %. While revenue at the Cytek Biosciences Inc 's corporate clients
Cytek Biosciences Inc's Comment on Sales, Marketing and Customers
Since mid-2017, the company has sold and deployed instruments worldwide to pharmaceutical companies, biopharma companies, academic research centers, and contract research organizations (CROs). Its solutions support research in oncology, immunology, and infectious diseases, and complement technologies such as next-generation sequencing (NGS). The company's FSP platform provides ultra-sensitive, high-content, flexible, efficient, compact, and integrated cell analysis capabilities. Following a February 2023 acquisition, the company also offers flow and image-based cytometry products under the Amnis and Guava brands, which are used in research areas including immunology and neurobiology.
In a remarkable convergence of technology and biological analysis, Cytek Biosciences is redefining the landscape of cellular diagnostics and analysis through a series of groundbreaking innovations. With the introduction of the SpectroPanel, an advanced automated panel design tool, alongside enhanced capabilities in small particle detection and the launch of a new facility in Wuxi, China, Cytek is poised to capitalize on increasing global demand for sophisticated cell analysis solutions. These developments not only position Cytek as a leader in the field but also underline the burgeoning importance of precise biological analysis in healthcare and research. Automated Panel Design with SpectroPanel At the foref...
In a pivotal move for increasing the rate of scientific discoveries, Cytek Biosciences, the leading biotechnology company, has recently announced a promising alliance with the Centre for Genomic Regulation (CRG) and The Pompeu Fabra University (UPF). The strategic agreement fosters a commitment towards bolstering advancements in the world of biosciences and highlights the ongoing mission of Cytek Biosciences to make a substantial impact on the healthcare industry.Cytek Biosciences is a trailblazer in the development and production of high-quality systems for cell analysis. With this collaboration, they are set to leverage the extensive research potential of the CRG and UPF. By providing both institutions wit...
Cytek Biosciences Inc., a trailblazer in the science industry, has pioneered a breakthrough with the introduction of the Cytek Orion Reagent Cocktail Preparation System. This novel creation, a first-of-its-kind automated cocktail preparation instrument for flow cytometry, promises to redefine the laboratory workflow by providing it with efficiency, consistency, and valuable time-saving benefits. Flow cytometry, a widely used method in laboratories for cell analysis, can often be a labor-intensive complex process. The innovative Orion reagent cocktail preparation system brings a revolution in this domain. By automating the process of reagent cocktail preparation, the Orion system simplifies and accelerates la...
Cytek Biosciences Inc’s Comment on Sales, Marketing and Customers
Since mid-2017, the company has sold and deployed instruments worldwide to pharmaceutical companies, biopharma companies, academic research centers, and contract research organizations (CROs). Its solutions support research in oncology, immunology, and infectious diseases, and complement technologies such as next-generation sequencing (NGS). The company's FSP platform provides ultra-sensitive, high-content, flexible, efficient, compact, and integrated cell analysis capabilities. Following a February 2023 acquisition, the company also offers flow and image-based cytometry products under the Amnis and Guava brands, which are used in research areas including immunology and neurobiology.
Sources:
Cytek Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Cytek Biosciences Inc’s corporate clients.
For your research, we’ve provided 9 tables on Cytek Biosciences Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
39.16 %